ロピナビル・リトナビル

ロピナビル・リトナビル 化学特性,用途語,生産方法

• 効能

  抗ウイルス薬

• 商品名

  カレトラ (アッヴィ); カレトラ (アッヴィ)

• 臨床応用

  Recently, the U.S. FDA has approved the release of lopinavir/ritonavir combination in patients who have not responded to other regimens for treatment of HIV. The product is available in a soft-gelatin capsule containing 133.3 mg of lopinavir and 33.3 mg of ritonavir as well as in oral solutions containing 80 mg/mL of lopinavir and 20 mg/mL of ritonavir. The small amount of ritonavir is not expected to have antiretroviral activity; rather, the ritonavir is meant to increase the plasma concentrations of lopinavir by inhibiting lopinavir's metabolism by CYP3A4 (ritonavir acts as a booster). These drugs, in combination with other antiretroviral agents, have been approved for use in adults as well as in patients between the ages of 6 months and 12 years. This is the first PI to be indicated for the very young.

ロピナビル・リトナビル 生産企業

Global(1)Suppliers